American Society of Hirudotherapy

Melasma (Investigational Adjunct)

Highly investigational adjunct for refractory melasma; uncontrolled reports only; sun protection, hydroquinone, tretinoin, tranexamic acid, and chemical peels remain primary.

Tier C — InvestigationalInvestigational: Limited human evidence exists (small trials, case series, or pilot studies). Use is investigational and should be considered carefully under clinician guidance.Last Updated: November 10, 2026 · ASH Editorial · based on the books

Patient Summary

Is this FDA-cleared for this use?
Not FDA-cleared for melasma. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, June 2004). Use for melasma is investigational.
What evidence exists?
Tier C (investigational). No controlled studies were identified; the only reports found are uncontrolled and come from Ayurvedic medicine (mostly single-patient case reports, plus a single-group study). Evidence-based therapy for melasma: triple combination cream (hydroquinone 4% + tretinoin 0.05% + fluocinolone 0.01%, Kligman formula), strict daily broad-spectrum SPF 50 mineral sunscreen, chemical peels (glycolic, salicylic), and tranexamic acid (oral or topical). Q-switched lasers in selected cases. PIH risk from leech application may worsen melasma in darker skin types.
Main risks
  • Bleeding from bite sites for 6 to 24 hours after detachment
  • Worsening of melasma through post-inflammatory hyperpigmentation
  • Permanent dark marks or scars at bite sites, especially on the face
  • Local skin infection or, rarely, Aeromonas infection from leech gut bacteria
  • Allergic reaction to leech saliva (uncommon)
  • Trigger of rebound hyperpigmentation after initial improvement
  • Delay of evidence-based topical therapy and sun protection
  • Cosmetic disfigurement that may be permanent
Who should not consider this
  • Patients with darker Fitzpatrick skin types (IV-VI) at very high PIH risk
  • Patients with active inflammatory skin disease at the planned bite site
  • Pregnant patients (melasma is hormonal — leech bites add risk without addressing cause)
  • Patients on anticoagulants or with anemia
  • Patients who have not tried triple combination cream and strict sun protection
  • Patients with photosensitivity or active sun-induced skin damage
What to ask your clinician
  • Have I tried Kligman's triple combination cream consistently for 12 weeks?
  • Am I using a broad-spectrum mineral SPF 50 sunscreen daily?
  • Have we addressed hormonal triggers (oral contraceptives, pregnancy, thyroid)?
  • Am I a candidate for oral or topical tranexamic acid?
  • What is the realistic risk of worsening pigmentation given my skin type?
  • Are leeches from an FDA-registered supplier and used only once?
  • What is the cost and is it covered by insurance? (typically not covered)
When to seek urgent care
  • Rapidly worsening or spreading pigmentation after treatment
  • Spreading redness, warmth, pus, or red streaks (cellulitis)
  • Fever above 38.0 C / 100.4 F or chills
  • Bleeding from a bite site lasting more than 24 hours
  • Hives, facial or tongue swelling, throat tightness, or breathing difficulty
  • New scarring or permanent dark marks at bite sites

What this does NOT mean

  • This is NOT FDA-cleared for melasma.
  • Anecdotal reports do NOT establish efficacy versus triple combination cream, tranexamic acid, or chemical peels.
  • It does NOT mean leech therapy is appropriate for facial pigmentary conditions — PIH risk often outweighs any benefit.
  • It does NOT address hormonal triggers (pregnancy, oral contraceptives) that drive melasma.
  • It does NOT substitute for evidence-based topical therapy plus strict daily sun protection.

Clinical Profile

Category
Dermatological
ICD-10
L81.1
Safety tier
Medium

Evidence Summary

Melasma management per the AAD includes strict sun protection (broad-spectrum SPF 50+, iron-oxide-containing visible-light protection), topical hypopigmenting agents (hydroquinone, the Kligman trio, azelaic acid, tranexamic acid), oral tranexamic acid (off-label), chemical peels, and laser therapy (with significant relapse risk). No controlled clinical study of leech therapy for melasma was identified in PubMed, Europe PMC or ClinicalTrials.gov. Two single-patient case reports from Ayurvedic journals were found (Kajal 2024; Bola 2025); they cannot establish efficacy. Its use is investigational and its rationale mechanistic only. The hormonal and UV-driven pathophysiology of melasma is unlikely to be addressed by peripheral leech application. Evidence is grade D.

Treatment specifics

How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: where the society's reference books describe a protocol, it is shown in the clinician view — switch the audience selector in the top bar to “Clinician”.)

Contraindications

  • Hemophilia or another bleeding disorder
  • Taking anticoagulants (blood thinners such as warfarin or heparin)
  • Anemia or suppressed blood formation
  • Low blood pressure, shock, collapse or fainting
  • Severe wasting (cachexia)
  • Intolerance of leeches or a history of severe allergic reactions
  • Pregnancy
  • Stomach or duodenal ulcer, erosive gastritis
  • Acute infectious disease or high fever
  • Severe unstable illness, markedly weakened immunity (for example during chemotherapy) or HIV infection
  • Drinking alcohol at the time of treatment
  • No consent from the patient
  • Pregnancy (chloasma)
  • Concurrent hormonal contraception driving hyperpigmentation (consider change)
  • Active inflammatory dermatosis at proposed site
  • Recent laser or chemical peel (<6 weeks)
  • Tendency to post-inflammatory hyperpigmentation (treatment may worsen)

Related Conditions

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.